 "Haffkine Institute gets govt's approval to produce Bharat Biotech's Covaxin")
Haffkine Institute, one of India's oldest biomedical research institutes, today received central government nod to produce Bharat Biotech's Covid-19 vaccine Covaxin on a technology transfer basis.
Department of biotechnology's secretary Renu Swarup conveyed the approval to Maharashtra chief secretary Sitaram Kunte on recommendation of an expert committee.
The approval comes in the backdrop of rising Covid-19 cases and government's effort to increase pace of vaccination through production ramp ups and quicker approvals.
Last month, Maharashtra Chief Minister Uddhav Thackeray had sought central nod to manufacture Bharat Biotech's Covaxin at Haffkine Institute. After a visit to the institute, Thackeray had said a manufacturing plant would be set up in partnership with Bharat Biotech to manufacture vaccines.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%